DNA拓扑异构酶Ⅰ在小细胞肺癌组织中的表达及其意义

目的探讨DNA拓扑异构酶I(Topo I)在小细胞肺癌(SCLC)组织中的表达及其临床意义。方法应用免疫组织化学S-P法,检测50例SCLC组织标本和12例正常肺组织标本中Topo I的表达情况。结果50例SCLC病理组织标本中,39例呈现Topo I的细胞核阳性表达,阳性率为78.0%(39/50);4个等级( 、 、 、 )的阳性率分别为34.0%(17/50)、18.0%(9/50)、10.0%(5/50)和16.0%(8/50)。12例正常肺组织中,3例出现阳性表达,阳性率为25.0%(3/12)。SCLC组与正常对照组比较,差异有统计学意义(P<0.05)。SCLC临床分期与Topo I表达呈正相关关系,随着临床分期的增高,Topo I阳性表达愈高。淋巴结转移阴性和阳性患者的Topo I表达阳性率分别为44.4%和85.4%,差异有统计学意义(P<0.05);Topo I表达与淋巴结转移相关,但与年龄、性别、吸烟指数、肿瘤大小、肿瘤部位无关(P>0.05)。结论肿瘤组织细胞中Topo I高表达是TopoI抑制剂应用于肿瘤治疗的理论根据,通过检测TopoI在SCLC组织中的表达情况,可预测患者是否对化疗药物敏感,提高疗效。

Expression and significance of DNA topoisomerase I (topo I) in small cell lung cancer

OBJECTIVE: To investigate the expression and its significance of DNA topoisomerase I (Topo I) in small cell lung cancer (SCLC). METHODS: Topo I expression was detected by immunohistochemical S-P technique on 50 cases of SCLC and 12 cases of normal lung tissues. RESULTS: The total positive rate of Topo I in normal lung tissue was 25.0% (3/12) and 78.0% (39/50) in SCLC. The expression of Topo I does not correlate with age, gender, smoking, tumor size and tumor site (P > 0.05), but significantly correlated with lymph node metastasis and clinical stage (P <0.05). CONCLUSION: High Topo I expression is a rationale indication of Topo I inhibitor treatment of malignancies. It should be possible to predict anti-tumor drug sensitivity by assessment of Topo I expression and help to improve the therapeutic efficacy for cancer patients.